ArticleJournal of microscopy and ultrastructure
The Antioxidant, Anti-inflammatory, and Anti-angiogenic Effects of Fucoxanthin on Corneal Structural and Biochemical Changes of Streptozotocin-induced Diabetes in Rats.
Article in Journal of microscopy and ultrastructure. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes mellitus is a worldwide disease with different endocrine and metabolic disorders due to hyperglycemia. Diabetic corneal complications affect more than 70% of diabetics. Fucoxanthin (FX) is a carotenoid that possesses antioxidant, anti-inflammatory, anti-angiogenic, and anti-diabetic effects. Materials and Methods: A total of 35 Wistar rats weighted 140-160 g of 12-14 weeks were divided into control; streptozotocin (STZ): rats received a single dose (50 mg/kg) of STZ intraperitoneally; STZ + FX low dose; STZ + FX intermediate dose; and STZ + FX high dose: diabetic rats treated with FX 100, 200, and 400 mg/kg, respectively, orally by an intragastric tube daily for 3 weeks. Then, blood and eye samples were managed for biochemical, histological, and immunohistochemical evaluations. Results: The STZ group revealed an increase in blood glucose level, plasma glycosylated hemoglobin A1c% significantly, and serum total cholesterol and low-density lipoprotein, malondialdehyde tissue levels, significantly reduced serum high-density lipoprotein, tissue superoxide dismutase, and reduced glutathione levels. In addition, severe corneal injury is seen by hematoxylin & eosin with deeply stained epithelial cell nuclei, and cytoplasm vacuolation, besides Bowman's membrane irregularities. Additionally, stromal widely separated collagen fibers, mononuclear cellular infiltrations, stromal vascularization, and swollen endothelial cells were seen. In addition, marked thickening of Bowman's and Descemet's membranes was demonstrated by periodic acid Schiff. In addition, E-cadherin diffuse cytoplasmic reaction, significantly increased immunohistochemical expression and optical density of interleukin-1β, metalloproteinase-3, and vascular endothelial growth factor, whereas significantly reduced the optical density of epidermal growth factor. The STZ-treated groups with different doses of FX showed dose-dependent improvement of the previously documented findings. Conclusion: FX ameliorates STZ-induced corneal changes in a dose-dependent manner in rats through its antioxidant, anti-inflammatory, anti-angiogenic, and anti-diabetic actions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.